Profile data is unavailable for this security.
About the company
Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
- Revenue in SEK (TTM)0.00
- Net income in SEK-125.83m
- Incorporated2011
- Employees10.00
- LocationInfant Bacterial Therapeutics ABBryggargatan 10STOCKHOLM 111 21SwedenSWE
- Phone+46 841014555
- Websitehttps://ibtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IRLAB Therapeutics AB | 98.99m | -78.08m | 328.30m | 30.00 | -- | 42.93 | -- | 3.32 | -1.42 | -1.42 | 1.80 | 0.0843 | 0.668 | -- | 7.41 | 3,666,222.00 | -52.69 | -27.34 | -142.49 | -32.01 | -33.55 | -45.70 | -78.88 | -112.19 | -- | -5.53 | 0.9349 | -- | 1,566.57 | 415.48 | 53.26 | -- | 7.75 | -- |
| Corline Biomedical AB | 8.09m | -24.60m | 336.75m | 12.00 | -- | 4.02 | -- | 41.62 | -1.09 | -1.09 | 0.3587 | 3.42 | 0.0848 | -- | 3.23 | 622,461.60 | -25.79 | -8.36 | -28.03 | -9.10 | 127.48 | 121.50 | -303.97 | -53.37 | -- | -485.83 | 0.00 | -- | -60.95 | 55.82 | -1,182.15 | -- | 9.13 | -- |
| Navamedic ASA | 512.23m | -10.72m | 365.17m | 45.00 | -- | 1.81 | 110.24 | 0.7129 | -0.7092 | -0.7092 | 31.00 | 12.13 | 1.08 | 2.97 | 6.21 | 12,918,740.00 | -2.26 | -0.3087 | -3.52 | -0.4895 | 39.78 | 39.37 | -2.09 | -0.2916 | 0.7247 | 0.9324 | 0.3431 | -- | 3.80 | 23.00 | 59.92 | -- | 35.76 | -- |
| Biohit Oyj | 159.63m | 28.70m | 421.67m | 46.00 | 18.31 | 3.85 | 12.54 | 2.64 | 0.1687 | 0.1687 | 0.9387 | 0.803 | 1.01 | 5.17 | 3.89 | 310,500.00 | 18.77 | 0.344 | 23.88 | 0.4349 | 65.24 | 63.49 | 18.68 | 0.3814 | 3.29 | -- | 0.0459 | 0.00 | 9.23 | 7.28 | 38.74 | -- | 54.27 | -- |
| Moberg Pharma AB (publ) | 12.86m | -251.38m | 432.56m | 9.00 | -- | 0.6049 | -- | 33.64 | -5.43 | -5.43 | 0.3024 | 14.68 | 0.0193 | 0.7155 | 2.61 | 1,428,889.00 | -37.66 | -- | -38.81 | -- | 65.23 | -- | -1,954.78 | -- | 18.06 | -- | 0.0054 | -- | -- | -- | -1,109.46 | -- | -- | -- |
| Magle Chemoswed Holding AB | 279.18m | 7.79m | 536.88m | 147.00 | 32.52 | 0.9697 | 9.37 | 1.92 | 0.7995 | 0.7995 | 18.38 | 26.81 | 0.4255 | 0.2303 | 13.76 | 1,899,184.00 | 1.19 | 2.43 | 1.81 | 3.45 | 93.17 | 88.63 | 2.79 | 4.76 | 0.2527 | 1.56 | 0.3701 | 0.00 | 38.49 | 13.10 | -1.91 | 74.06 | -21.72 | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -125.83m | 626.17m | 10.00 | -- | 4.22 | -- | -- | -9.34 | -9.34 | 0.00 | 11.40 | 0.00 | -- | -- | 0.00 | -45.20 | -22.82 | -58.41 | -24.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.24 | -- | -- | -- |
| Orexo AB | 597.00m | -210.00m | 690.74m | 104.00 | -- | -- | -- | 1.16 | -6.08 | -6.08 | 17.30 | -4.67 | 0.8787 | 1.47 | 2.95 | 5,427,273.00 | -30.92 | -14.99 | -103.98 | -23.52 | 86.68 | 86.76 | -35.19 | -26.50 | 1.55 | -2.37 | 1.50 | -- | -7.64 | -6.93 | -58.22 | -- | -31.86 | -- |
| Enzymatica AB (publ) | 48.43m | -52.32m | 706.36m | 21.00 | -- | 4.47 | -- | 14.58 | -0.2437 | -0.2437 | 0.2281 | 0.6508 | 0.3046 | 0.9925 | 8.02 | 2,306,381.00 | -32.90 | -29.10 | -35.23 | -34.48 | 67.59 | 63.82 | -108.02 | -73.32 | -- | -63.92 | 0.0118 | -- | -10.47 | -5.76 | -6.94 | -- | -14.62 | -- |
Data as of Jul 11 2025. Currency figures normalised to Infant Bacterial Therapeutics AB's reporting currency: Swedish Krona SEK
39.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 07 May 2024 | 1.34m | 10.32% |
| Keel Capital ABas of 08 Jan 2024 | 666.05k | 5.12% |
| Premier Fund Managers Ltd.as of 28 Feb 2025 | 611.56k | 4.70% |
| AMF Fonder ABas of 07 May 2024 | 601.90k | 4.62% |
| Tredje AP-fondenas of 07 May 2024 | 523.37k | 4.02% |
| SEB Investment Management ABas of 31 Dec 2023 | 443.25k | 3.41% |
| �landsbanken Fondbolag AB (Sweden)as of 07 May 2024 | 409.52k | 3.15% |
| Banque Pictet & Cie SA (Investment Management)as of 07 May 2024 | 311.17k | 2.39% |
| Baader Bank AG (Investment Management)as of 30 Apr 2025 | 166.38k | 1.28% |
| Handelsbanken Fonder ABas of 30 Jun 2025 | 75.70k | 0.58% |
More ▼
Data from 31 Dec 2024 - 30 Jun 2025Source: FactSet Research Systems Inc.
